MARKET

OMER

OMER

Omeros
NASDAQ
17.18
+0.22
+1.27%
After Hours: 17.80 +0.62 +3.62% 19:59 12/31 EST
OPEN
16.68
PREV CLOSE
16.96
HIGH
17.35
LOW
16.13
VOLUME
2.81M
TURNOVER
--
52 WEEK HIGH
17.65
52 WEEK LOW
2.950
MARKET CAP
1.22B
P/E (TTM)
-8.5122
1D
5D
1M
3M
1Y
5Y
1D
Omeros call volume above normal and directionally bullish
TipRanks · 12/29/2025 16:45
Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options
NASDAQ · 12/29/2025 16:42
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
NASDAQ · 12/29/2025 15:57
Weekly Report: what happened at OMER last week (1222-1226)?
Weekly Report · 12/29/2025 09:49
Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade)
Seeking Alpha · 12/29/2025 07:45
FDA Approves Omeros' YARTEMLEA for TA-TMA
Reuters · 12/26/2025 23:36
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
Barchart · 12/26/2025 17:36
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 12/26/2025 13:03
More
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.